Abstract |
The initial management of immune thrombocytopenic purpura is a topic of debate among pediatric hematologists. The decision whether to start a patient on pharmacotherapy or to employ an approach of watchful waiting and patient education is problematic for this group of physicians. A wide variety of research studies and review articles have been published on either side of this debate. Here, the proceedings from a panel discussion, held at the 2002 American Society of Pediatric Hematology/Oncology meeting, are presented. The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy.
|
Authors | Paula Bolton-Maggs, Michael D Tarantino, George R Buchanan, James B Bussel, James N George, American Society of Pediatric Hematology/Oncology |
Journal | Journal of pediatric hematology/oncology
(J Pediatr Hematol Oncol)
Vol. 26
Issue 2
Pg. 146-51
(Feb 2004)
ISSN: 1077-4114 [Print] United States |
PMID | 14767210
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Immunoglobulins, Intravenous
- Isoantibodies
- RHO(D) antibody
- Rho(D) Immune Globulin
|
Topics |
- Adolescent
- Child
- Child, Preschool
- Female
- Glucocorticoids
(therapeutic use)
- Humans
- Immunoglobulins, Intravenous
(administration & dosage)
- Infant
- Isoantibodies
(administration & dosage, immunology)
- Male
- Purpura, Thrombocytopenic, Idiopathic
(drug therapy)
- Rho(D) Immune Globulin
|